货号:A730331
同义名:
盐酸雷诺嗪;雷诺嗪二盐酸盐
/ CVT 303 dihydrochloride; RS 43285
Ranolazine 2HCl 是一种钙摄取抑制剂,通过钠/钙通道发挥作用,常用于慢性心绞痛的研究。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | Ca2+ channel-like protein ↓ ↑ | Calcium Channel ↓ ↑ | Cav 2.2 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CDC25B-IN-2 | ✔ | Akt | 99%+ | ||||||||||||||||
| Clevidipine | ✔ | 97% | |||||||||||||||||
| Verapamil HCl | ✔ | 99% | |||||||||||||||||
| Amlodipine | ✔ | 99% | |||||||||||||||||
| Amlodipine maleate | ✔ | 98% | |||||||||||||||||
| (+)-cis-Diltiazem HCl | ✔ | 99% | |||||||||||||||||
| Zegocractin |
++
Orai1/STIM1-mediated Ca2+ currents, IC50: 120 nM |
99%+ | |||||||||||||||||
| Tanshinone IIA sulfonate sodium | ✔ | 98% | |||||||||||||||||
| Ulixacaltamide |
++
hCaV3.1, IC50: 50 nM hCaV3.2, IC50: 110 nM |
99%+ | |||||||||||||||||
| Dronedarone HCl | ✔ | 95% | |||||||||||||||||
| Nitrendipine |
+
Calcium channel, IC50: 95 nM |
98% | |||||||||||||||||
| Efonidipine HCl monoethanolate | ✔ | 98% | |||||||||||||||||
| Cinnarizine | ✔ | 98% | |||||||||||||||||
| SEA0400 |
++
NCX, IC50: 33 nM |
ERK,ROS,p38 MAPK | 99%+ | ||||||||||||||||
| Fasudil HCl | ✔ | PKA,Rho | 98% | ||||||||||||||||
| ML-9 | ✔ | Akt,MLCK | 99%+ | ||||||||||||||||
| Flunarizine 2HCl |
+
Calcium channel, Ki: 68 nM |
95% | |||||||||||||||||
| Lomerizine 2HCl | ✔ | 98% | |||||||||||||||||
| Efonidipine | ✔ | 98% | |||||||||||||||||
| Levamlodipine | ✔ | 98% | |||||||||||||||||
| Nisoldipine |
++
L-type Cav1.2, IC50: 10 nM |
97% | |||||||||||||||||
| Isradipine | ✔ | 98% | |||||||||||||||||
| Lacidipine | ✔ | 98% | |||||||||||||||||
| Lercanidipine | ✔ | 99% | |||||||||||||||||
| Loureirin B | ✔ | Potassium Channel | 99%+ | ||||||||||||||||
| Tetracaine HCl | ✔ | 98% | |||||||||||||||||
| Manidipine |
+++
Calcium channel, IC50: 2.6 nM |
99% | |||||||||||||||||
| Manidipine Dihydrochlorid |
+++
Calcium channel, IC50: 2.6 nM |
98% | |||||||||||||||||
| Nicardipine | ✔ | 99% | |||||||||||||||||
| Wilforgine | ✔ | 98+% | |||||||||||||||||
| Econazole | ✔ | 99%+ | |||||||||||||||||
| Ginsenoside Rd | ✔ | NF-κB | 98% | ||||||||||||||||
| Fendiline HCl | ✔ | 98+% | |||||||||||||||||
| Mesaconitine | ✔ | 98% | |||||||||||||||||
| Tetrandrine | ✔ | 95% | |||||||||||||||||
| Nifedipine | ✔ | 98% | |||||||||||||||||
| Nilvadipine |
++++
Calcium channel, IC50: 0.03 nM |
95% | |||||||||||||||||
| Barnidipine |
++++
[3H]nitrendipine, Ki: 0.21 nM |
95+% | |||||||||||||||||
| Azelnidipine | ✔ | 97% | |||||||||||||||||
| Levetiracetam | ✔ | 98% | |||||||||||||||||
| Nimodipine | ✔ | 95% | |||||||||||||||||
| Benidipine HCl | ✔ | 98% | |||||||||||||||||
| Pinaverium bromide | ✔ | 98% | |||||||||||||||||
| Pranidipine | ✔ | 99% | |||||||||||||||||
| NP118809 |
+
L-type calcium channel, IC50: 12.2 μM N-type Ca2+ channel, IC50: 0.11 μM |
95% | |||||||||||||||||
| Amlodipine Besylate |
+++
Calcium channel, IC50: 1.9 nM |
97% | |||||||||||||||||
| Cilnidipine | ✔ | 99% | |||||||||||||||||
| Cinepazide Maleate | ✔ | 99% (HPLC) | |||||||||||||||||
| Terfenadine | ✔ | 98% | |||||||||||||||||
| YM-58483 | ✔ | 99%+ | |||||||||||||||||
| Amiloride HCl | ✔ | 98% | |||||||||||||||||
| Ranolazine | ✔ | 98% | |||||||||||||||||
| Praeruptorin A | ✔ | Akt,p38 MAPK | 98% | ||||||||||||||||
| Ranolazine 2HCl | ✔ | 98% | |||||||||||||||||
| Felodipine |
++++
L-type calcium channel, IC50: 0.15 nM |
98% | |||||||||||||||||
| PD173212 |
+++
N-type Ca2+ channel, IC50: 36 nM |
98% | |||||||||||||||||
| Levamlodipine besylate | ✔ | 97% | |||||||||||||||||
| Carboxyamidotriazole Orotate | ✔ | 98% | |||||||||||||||||
| IGS-1.76 | ✔ | 98+% | |||||||||||||||||
| WH-4-023 |
++++
Cav 2.2, IC50: 0.001 μM |
++++
Cav 2.2, IC50: 0.001 μM |
99%+ | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 产品名称 | Sodium Channel ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tolperisone HCl | ✔ | 99% | |||||||||||||||||
| Triamterene |
+++
ENaC, IC50: 4.5 μM |
98% | |||||||||||||||||
| Lamotrigine | ✔ | 98% | |||||||||||||||||
| Vinpocetine | ✔ | 98% | |||||||||||||||||
| Zonisamide | ✔ | 99% | |||||||||||||||||
| Dronedarone HCl | ✔ | 95% | |||||||||||||||||
| Procainamide HCl | ✔ | 99% | |||||||||||||||||
| Bupivacaine HCl | ✔ | 99+% | |||||||||||||||||
| Benzocaine | ✔ | 98% | |||||||||||||||||
| Carbamazepine |
++
Sodium channel, IC50: 131 μM |
98% | |||||||||||||||||
| Quinidine sulfate dihydrate | ✔ | 98% | |||||||||||||||||
| Ibutilide fumarate | ✔ | 99%+ | |||||||||||||||||
| Dibucaine HCl | ✔ | 99+% | |||||||||||||||||
| Mexiletine HCl | ✔ | 99% | |||||||||||||||||
| Phenytoin | ✔ | 99+% | |||||||||||||||||
| Camostat Mesylate |
+++
epithelial sodium channel (ENaC), IC50: 50 nM |
99%+ | |||||||||||||||||
| Levobupivacaine | ✔ | 97+% | |||||||||||||||||
| Oxcarbazepine |
+
sodium channel, IC50: 160 μM |
98% | |||||||||||||||||
| Amiloride HCl dihydrate | ✔ | 97% | |||||||||||||||||
| Ambroxol | 98+% | ||||||||||||||||||
| Primidone | ✔ | 99% | |||||||||||||||||
| Propafenone | ✔ | 99% | |||||||||||||||||
| A-803467 |
++++
Na(V1.8) channel, IC50: 8 nM |
99%+ | |||||||||||||||||
| Rufinamide | ✔ | 99% | |||||||||||||||||
| Phenytoin sodium | ✔ | 98% | |||||||||||||||||
| Proparacaine HCl |
+
Voltage-gated sodium channel, ED50: 3.4 mM |
98+% | |||||||||||||||||
| Amiloride HCl | ✔ | 98% | |||||||||||||||||
| Riluzole | ✔ | 97% | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | Ranolazine 2HCl is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP). Ranolazine ER (Extended-release) was generally well tolerated, with the most commonly reported adverse events including dizziness, nausea, asthenia and constipation[3]. Ranolazine antagonizes the ventricular repolarization changes caused by clofilium and suppresses clofilium-induced TdP (Torsade de Pointes) in rabbits[4]. Ranolazine reduces cellular acetyl-CoA content via inhibition of fatty acid beta-oxidation and activates pyruvate dehydrogenase. Ranolazine (bolus injection: 10 mg/kg plus infusion: 9.6 mg/kg/h, n=12) significantly reduces (i) infarct size and (ii) cardiac troponin T release in rats subjected to left anterior descending coronary artery occlusion-reperfusion[5]. Ranolazine improved learning and long-term memory in HFD/STZ + Ranolazine compared to HFD/STZ + Vehicle and ameliorated the pro-inflammatory profile of diabetic mice[6]. |
| Concentration | Treated Time | Description | References | |
| HEK293T cells | 10 µmol/L | Empagliflozin significantly inhibited late-INa in R1623Q and ΔKPQ mutant Nav1.5 channels | Circulation. 2021 Jun;143(22):2188-2204. | |
| Mouse cardiomyocytes | 10 µmol/L | Empagliflozin significantly inhibited late-INa in cardiomyocytes from mice with heart failure, restoring it to levels similar to those in sham-operated controls | Circulation. 2021 Jun;143(22):2188-2204. | |
| WM9 cells | 50 µM or 100 µM | Once per week | To assess the effect of Ranolazine on the development of BRAF inhibitor resistance, results showed that Ranolazine significantly reduced the establishment of acquired resistance colonies | Nat Metab. 2023 Sep;5(9):1544-1562. |
| A375 cells | 100 µM | Once per week | To assess the effect of Ranolazine on the development of BRAF inhibitor resistance, results showed that Ranolazine significantly reduced the establishment of acquired resistance colonies | Nat Metab. 2023 Sep;5(9):1544-1562. |
| HEK cells (expressing NaV1.5) | 50 μM | 10 minutes | Ranolazine blocks current at rest and inhibits the mechanical activation of NaV1.5 expressed in HEK cells. | Circulation. 2012 Jun 5;125(22):2698-706. |
| Murine ventricular cardiac myocytes | 50 μM | 10 minutes | Ranolazine not only blocks peak NaV current but also inhibits the response of NaV channels to mechanical stimulation by bath flow. | Circulation. 2012 Jun 5;125(22):2698-706. |
| MDA-MB-231-Luc cells | 50 μM | 24 hours | Inhibited Na V1.5 currents and reduced breast cancer cell invasiveness | Mol Cancer. 2014 Dec 11;13:264. |
| Detergent extracted fiber bundles | 10 μmol/L | 15 minutes | To evaluate the effect of Ranolazine on myofilament Ca2+ sensitivity and cross-bridge kinetics. Results showed that Ranolazine reduced maximum tension and Ca2+ sensitivity in DOCA-salt fiber bundles, restoring them to levels similar to controls. | Circ Res. 2012 Mar 16;110(6):841-50. |
| Cardiomyocytes | 10 μmol/L | 10 minutes | To evaluate the effect of Ranolazine on diastolic function in DOCA-salt cardiomyocytes. Results showed that Ranolazine significantly improved diastolic function, normalizing the relaxation time constant τ. | Circ Res. 2012 Mar 16;110(6):841-50. |
| Administration | Dosage | Frequency | Description | References | ||
| Nude mice | A375 human melanoma xenograft model | Intraperitoneal injection | 50 mg/kg | Once daily for up to 50 days | To assess the effect of Ranolazine on BRAF inhibitor therapy, results showed that Ranolazine significantly reduced tumor growth and delayed the onset of resistance | Nat Metab. 2023 Sep;5(9):1544-1562. |
| NMRI nude mice | Immunodepressed mice model | Intraperitoneal injection | 50 mg/kg/day | 5 days per week for 8 weeks | Significantly reduced lung colonization by Na V1.5-expressing human breast cancer cells | Mol Cancer. 2014 Dec 11;13:264. |
| Mice | SGK1-CA transgenic mice | Subcutaneous implantation | 140 mg/pellet (two 14-day release pellets) | 7 days | To study the effect of ranolazine on QT interval, cardiac function, and arrhythmias in SGK1-CA mice | Circulation. 2012 Oct 30;126(18):2208-19. |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.00mL 0.40mL 0.20mL |
9.99mL 2.00mL 1.00mL |
19.98mL 4.00mL 2.00mL |
|
| CAS号 | 95635-56-6 |
| 分子式 | C24H35Cl2N3O4 |
| 分子量 | 500.46 |
| SMILES Code | O=C(NC1=C(C)C=CC=C1C)CN2CCN(CC(O)COC3=CC=CC=C3OC)CC2.[H]Cl.[H]Cl |
| MDL No. | MFCD03788770 |
| 别名 | 盐酸雷诺嗪;雷诺嗪二盐酸盐 ;CVT 303 dihydrochloride; RS 43285; Ranolazine(hydrochloride); Ranolazine dihydrochloride |
| 运输 | 蓝冰 |
| InChI Key | RJNSNFZXAZXOFX-UHFFFAOYSA-N |
| Pubchem ID | 71279 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry,2-8°C |
| 溶解方案 |
DMSO: 50 mg/mL(99.91 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO H2O: 50 mg/mL(99.91 mM)
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1